Delivery Order SPE2DB22D9244-SPE2DB25FZS12

Award Date 5/28/25
Potential Completion Date 6/18/25
Potential Value $14K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the supply of 1,000 unit vials of the drug KCENTRA. The order, valued at $72,075.36, has an ultimate completion date of June 21, 2024. DMS Pharmaceutical Group holds a significant indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999, which allows the agency to issue delivery orders for a...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of 1,000 unit vials of the pharmaceutical product KCENTRA, with a ceiling value of $12,743.68 and a period of performance through May 6, 2025. This delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical...
The Defense Logistics Agency (DLA) awarded a delivery order contract to DMS Pharmaceutical Group Inc., a for-profit, woman-owned small business located in Park Ridge, Illinois. The contract is for the delivery of 1,000 unit vials of the pharmaceutical product KCENTRA with a firm fixed price of $15,944.80 and a completion date of March 27, 2024. This delivery order is part of a larger indefinite delivery vehicle (IDV) contract, number 4600082013 under the SPE2DB program, that DMS Pharmaceutical...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $3,432.16, is for the delivery of 1,000 unit vials of the medication KCENTRA. The delivery order has a completion date of June 24, 2024. DMS Pharmaceutical Group holds a larger Indefinite Delivery Contract (IDC) with the DLA, valued up to $499,999,999, that...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract, valued at $13,230.08, is for the supply of 1,000-unit vials of the pharmaceutical product KCENTRA. There is no set-aside designation for this award. The contract is part of DMS Pharmaceutical Group's larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which has a...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The $16,020.80 firm fixed-price contract is for the delivery of 1,000 unit vials of the pharmaceutical product KCENTRA, with a completion date of June 6, 2025. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue delivery orders for...
This contract was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $20,592.96, is for the delivery of 1,000 unit vials of the drug KCENTRA. The contract is a firm fixed-price delivery order, with an ultimate completion date of June 17, 2024. DMS Pharmaceutical Group holds a significant indefinite delivery contract (IDC) with the DLA, valued at up to...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of 1,000 unit vials of the medication KCENTRA, with a ceiling value of $3,198.08 and a completion date of April 3, 2025. DMS Pharmaceutical Group Inc. is a key supplier in the federal pharmaceutical supply chain, providing a comprehensive range of...
This is a firm fixed-price delivery order (SPE2DB22D9316|SPE2DB24FYN87) awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a for-profit, woman-owned small business, for the supply of 4,564,261,457 units of the pharmaceutical product KCENTRA 500 UNIT VIALS. The order has an ultimate completion date of May 2, 2024 and a ceiling value of $10,323.84. DMS Pharmaceutical Group Inc. holds an indefinite delivery contract (4600082013) with DLA under the SPE2DB program, valued...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the provision of 4,565,252,938 units of KCENTRA 1,000 unit vials. The $34,139.20 contract has an ultimate completion date of August 13, 2024. DMS Pharmaceutical Group is a key supplier in the federal pharmaceutical supply chain, providing a comprehensive range of medications and medical supplies to support the...
  • SPE2DB22D9244
    Indefinite Delivery Contract
  • SPE2DB22D9244-SPE2DB25FZS12
    Delivery Order

This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business located in Park Ridge, Illinois. The contract is for the delivery of 1,000 unit vials of the pharmaceutical product KCENTRA, with a ceiling value of $13,704.32 and a completion date of June 18, 2025. DMS Pharmaceutical Group holds a significant Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026, which enables the agency to issue delivery orders for a wide range of pharmaceutical products to support the medical supply needs of military health facilities worldwide.

Generated 8/27/25, 9:43 AM